Most New Patients In Japan Take DPP-4 Inhibitor As First Choice
This article was originally published in PharmAsia News
Executive Summary
More than 50% of patients with type 2 diabetes in Japan are prescribed a DPP-4 inhibitor, according to a JMIRI survey on prescribed oral hypoglycemic agents.